Display Settings:

Format

Send to:

Choose Destination
    Methods Mol Biol. 2011;793:495-508.

    Evaluation of histone deacetylase inhibitors as therapeutics for neurodegenerative diseases.

    Source

    Department of Molecular Biology, The Scripps Research Institute, La Jolla, CA, USA.

    Abstract

    Various neurodegenerative diseases are associated with aberrant gene expression. We recently identified a novel class of pimelic o-aminobenzamide histone deacetylase (HDAC) inhibitors that show promise as therapeutics in the neurodegenerative diseases Friedreich's ataxia (FRDA) and Huntington's disease (HD). Here, we describe the various techniques used in our laboratories to dissect mechanisms of gene silencing in FRDA and HD, and to test our HDAC inhibitors for their ability to reverse changes in gene expression in cellular models.

    PMID:
    21913121
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Springer

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk